Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment

• Main Authors: Sukit Saengnipanthkul, Saranatra Waikakul, Sattaya Rojanasthien, Kitti Totemchokchyakarn, Attarit Srinkapaibulaya, Tai Cheh Chin, Nguyen Mai Hong, Olivier Bruyère, Cyrus Cooper, Jean Yves Reginster, Myat Lwin
• 格式: 雜誌
• 出版: 2019
• 主題: Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85017162564&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/65785

© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are recommended for the medium- to long-term management of knee osteoarthritis (OA) due to their abilities to control pain, improve funct...